{Reference Type}: Journal Article
{Title}: Radiation therapy for retroperitoneal sarcoma: practice patterns in North America.
{Author}: Ruff SM;Heh V;Konieczkowski DJ;Onuma A;Dunlop HM;Kim AC;Grignol VP;Contreras CM;Pawlik TM;Pollock R;Beane JD;
{Journal}: Radiat Oncol
{Volume}: 19
{Issue}: 1
{Year}: 2024 Mar 16
{Factor}: 4.309
{DOI}: 10.1186/s13014-024-02407-8
{Abstract}: <B>BACKGROUND: </B>The addition of radiation therapy (RT) to surgery in retroperitoneal sarcoma (RPS) remains controversial. We examined practice patterns in the use of RT for patients with RPS over time in a large, national cohort.<BR><B>METHODS: </B>Patients in the National Cancer Database (2004-2017) who underwent resection of RPS were included. Trends over time for proportions were calculated using contingency tables with Cochran-Armitage Trend test.<BR><B>RESULTS: </B>Of 7,485 patients who underwent resection, 1,821 (24.3%) received RT (adjuvant: 59.9%, neoadjuvant: 40.1%). The use of RT decreased annually by < 1% (p = 0.0178). There was an average annual increase of neoadjuvant RT by 13% compared to an average annual decrease of adjuvant RT by 6% (p < 0.0001). Treatment at high-volume centers (OR 14.795, p < 0.0001) and tumor > 10 cm (OR 2.009, p = 0.001) were associated with neoadjuvant RT. In contrast liposarcomas (OR 0.574, p = 0.001) were associated with adjuvant RT. There was no statistically significant difference in overall survival between patients treated with surgery alone versus surgery and RT (p = 0.07).<BR><B>CONCLUSIONS: </B>In the United States, the use of RT for RPS has decreased over time, with a shift towards neoadjuvant RT. However, a large percentage of patients are still receiving adjuvant RT and this mostly occurs at low-volume hospitals.